Aster DM Healthcare Ltd

Aster DM Healthcare has received the approval from Competition Commission of India (CCI) vide letter dated 15 April 2025 for the proposed transaction detailed below: 1. Acquisition of 1,90,46,028 equity shares of the face value of Rs 10 each held by BCP Asia II TopCo IV (BCP) and Centella Mauritius Holdings (Centella) and together with BCP, (QCIL Shareholders) in Quality Care India (QCIL) for consideration other than cash, being the issuance and allotment of 1,86,07,969 equity shares of the Company of the face value of Rs 10 each fully paid up, on a preferential basis to the QCIL Shareholders (Share Swap); 2. A scheme of amalgamation (Scheme) between the Company and QCIL and their respective shareholders and creditors under Section 230 to 232 of the Companies Act, 2013 and the rules framed thereunder read with relevant circulars and regulations of SEBI, and other applicable laws, for amalgamation of QCIL into the Company by way of merger (by absorption) as a going concern in consideration for the issuance and allotment of the equity shares of the Company to the shareholders of QCIL (other than the Company) in accordance with the share exchange ratio as stipulated in the Scheme (Merger and together with Share Swap, the Proposed Transactions).  Powered by Capital Market - Live

Bayer CropScience Ltd, Timken India Ltd, DCM Shriram Ltd, Indian Overseas Bank are among the other stocks to see a surge in volumes on NSE today, 28 March 2025.Aster DM Healthcare Ltd saw volume of 154.37 lakh shares by 14:14 IST on NSE, a 24.95 fold spurt over two-week average daily volume of 6.19 lakh shares. The stock increased 6.19% to Rs.481.40. Volumes stood at 9.37 lakh shares in the last session.Bayer CropScience Ltd saw volume of 3.58 lakh shares by 14:14 IST on NSE, a 12.08 fold spurt over two-week average daily volume of 29657 shares. The stock increased 4.96% to Rs.4,942.00. Volumes stood at 86238 shares in the last session.Timken India Ltd notched up volume of 8.36 lakh shares by 14:14 IST on NSE, a 6.83 fold spurt over two-week average daily volume of 1.22 lakh shares. The stock rose 0.73% to Rs.2,729.45. Volumes stood at 3.79 lakh shares in the last session.DCM Shriram Ltd notched up volume of 6.51 lakh shares by 14:14 IST on NSE, a 6.5 fold spurt over two-week average daily volume of 1.00 lakh shares. The stock slipped 0.71% to Rs.1,096.00. Volumes stood at 4.14 lakh shares in the last session.Indian Overseas Bank clocked volume of 372.94 lakh shares by 14:14 IST on NSE, a 4.42 times surge over two-week average daily volume of 84.31 lakh shares. The stock lost 6.47% to Rs.39.05. Volumes stood at 193.9 lakh shares in the last session.Powered by Capital Market - Live

Bayer CropScience Ltd, Mahindra Holidays & Resorts India Ltd, Timken India Ltd, Carborundum Universal Ltd are among the other stocks to see a surge in volumes on BSE today, 28 March 2025.Aster DM Healthcare Ltd registered volume of 17.76 lakh shares by 10:47 IST on BSE, a 76.46 fold spurt over two-week average daily volume of 23225 shares. The stock rose 2.12% to Rs.462.85. Volumes stood at 24618 shares in the last session.Bayer CropScience Ltd saw volume of 6244 shares by 10:47 IST on BSE, a 4.74 fold spurt over two-week average daily volume of 1317 shares. The stock increased 7.46% to Rs.5,070.70. Volumes stood at 1823 shares in the last session.Mahindra Holidays & Resorts India Ltd witnessed volume of 46794 shares by 10:47 IST on BSE, a 3.51 times surge over two-week average daily volume of 13328 shares. The stock increased 0.77% to Rs.295.00. Volumes stood at 49993 shares in the last session.Timken India Ltd notched up volume of 7923 shares by 10:47 IST on BSE, a 3.15 fold spurt over two-week average daily volume of 2513 shares. The stock rose 5.90% to Rs.2,875.00. Volumes stood at 7320 shares in the last session.Carborundum Universal Ltd clocked volume of 61602 shares by 10:47 IST on BSE, a 2.99 times surge over two-week average daily volume of 20637 shares. The stock gained 5.64% to Rs.1,019.40. Volumes stood at 36592 shares in the last session.Powered by Capital Market - Live

However, revenue from operations jumped 9.96% year on year (YoY) to Rs 1,049.81 crore during the quarter ended 31 December 2024. Profit before tax rallied 32.98% to Rs 101.88 crore in Q3 of FY25, from Rs 76.61 crore posted in the corresponding quarter last year. EBITDA stood at Rs 202 crore in the December 2024 quarter, up 20% as compared with Rs 168 crore in Q3 FY24. EBITDA margin expanded to 19.3% in Q3 FY25 as against 17.7% in Q3 FY24. Dr. Azad Moopen, Founder and Chairman, Aster DM Healthcare, said: 'We are pleased with the momentum built in the third quarter of FY25, which reflects our unwavering focus on operational excellence and capacity enhancement. For 9M FY25, our India business achieved 15% YoY growth, reaching Rs 3,138 crore, driven by increased patient volumes and growth in ARPOB. The operating EBITDA grew by 35% YoY to Rs 613 crore, and adjusted net profits (post NCI and excluding merger transaction cost) grew by 65% YoY to Rs 251 crore for 9M FY25. A consistent growth across our core businesses, combined with strategic cost optimization, has significantly strengthened our margins, with 9MFY25 operating EBITDA margins standing at 19.5%.' Dr. Moopen further added, 'As we expand, with plans to surpass 6,800 beds by FY27, Aster DM Healthcare is well-positioned to meet the increasing demand for advanced healthcare in India. I am happy to announce that Aster DM Healthcare was recently honored at the ASSOCHAM Healthcare Awards 2024, winning the title of Best Multispecialty Hospital-Group, while Aster DM Foundation secured a 1st runner-up for Best CSR Excellence in Healthcare.'. Meanwhile, the company has received shareholder approval for the issuance of equity shares on a preferential basis to eligible shareholders of Quality Care India (QCIL) and for the change in the company's registered office. The application seeking approval for the preferential allotment to QCIL's eligible shareholders, the acquisition of approximately a 5% stake in QCIL, and the subsequent merger has been filed with the Competition Commission of India (CCI) for their approval. Additionally, an application has been submitted to the stock exchange for approval of the merger, and the company will soon file the application for the change in registered office with the Regional Director, South-East Region, Telangana. The closing of the transaction is pending the fulfillment of regulatory and compliance requirements, including the receipt of no-objection letters from the stock exchanges, as well as approvals from CCI and the National Company Law Tribunal (NCLT). Further, the board has declared an interim dividend of Rs 4 per share, as on the record date, i.e., 7 February 2025. The date of payment of the interim dividend will be on or before Monday, 10 February 2025. Aster DM Healthcare is primarily involved in the operations of healthcare facilities, retail pharmacies, and providing consultancy in areas relating to healthcare. Powered by Capital Market - Live

Aster DM Healthcare announced that the Board of Directors of the Company at its meeting held on 31 January 2025, inter alia, have recommended the interim dividend of Rs 4 per equity Share (i.e. 40%) , subject to the approval of the shareholders.Powered by Capital Market - Live

Net profit of Aster DM Healthcare declined 68.31% to Rs 56.79 crore in the quarter ended December 2024 as against Rs 179.21 crore during the previous quarter ended December 2023. Sales rose 9.97% to Rs 1049.81 crore in the quarter ended December 2024 as against Rs 954.67 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales1049.81954.67 10 OPM %17.6815.63 - PBDT187.81133.12 41 PBT125.6076.61 64 NP56.79179.21 -68 Powered by Capital Market - Live

Aster DM Healthcare has fixed 10 February 2025 as record date for determining entitlement of the shareholders to the interim dividend for the FY 2024-25. Powered by Capital Market - Live

Aster DM Healthcare will hold a meeting of the Board of Directors of the Company on 31 January 2025.Powered by Capital Market - Live

Securities in F&O Ban : Bandhan Bank, Granules India, Hindustan Copper, Manappuram Finance, RBL Bank Stocks to Watch: Whirlpool of India has signed a definitive agreement with PG Electroplast for the contract manufacturing of select mode of Whirlpool-branded semi automatic washing machines. PG Electroplast will manufacture some of the SKUs for Whirlpool at its factory in Roorkee. PG Electroplast is already an existing supplier of whirlpool-branded air conditioners Aster DM Healthcare board has approved Nalanda Jayadev as chief executive officer (CEO) of Aster Medcity Kochi & Senior Consultant - Forensic Medicine, with effect from 23 December 2024. HG Infra Engineering 's subsidiary, HG Banaskantha Bess, has entered into a battery energy storage purchase agreement with NTPC Vidyut Vyapar Nigam for procurement of 185 MW/ 370 MWH on long term basis. MIC Electronics reported that competent authority had approved the capacity cum capability assessment (CCA) of the company GPS Location based public address & passenger information system (PAPIS) and LED destination boards in AC and Non -AC ICF & LHB Coaches Dr Reddy's Laboratories SA, Switzerland, a wholly owned subsidiary of the company, has incorporated a new wholly owned subsidiary in Finland, Dr Reddy's Finland Oy. Meanwhile, the company's board will meet on 23 January 2025 to consider and approve the Unaudited Financial Results of the Company for the quarter and nine months ending on December 31, 2024. Nava's shareholders approved the sub-division / split of equity shares of the company in the ratio of (1:2), 1 existing equity share of face value of Re 1 each fully paid up into 2 equity shares of face value of Re 1 each fully paid up.Powered by Capital Market - Live

Quality Care India Limited (QCIL) engaged in healthcare business and related services through a network of multi-specialty healthcare establishments across India and Bangladesh that it or its subsidiaries own or operate from time to time. Its standalone turnover was Rs 1,136.33 crore in FY24. Ahead of this merger, Aster shall purchase 5% stake or 1,90,46,028 crore shares at Rs 445.8 per share in QCIL from Blackstone and TPG in consideration of primary share issuance by Aster for 3.6% stake or 1,86,07,969 crore equity shares at Rs 456.33 per share. The acquisition will require an in-principle approval of the stock exchanges and the approval of the Competition Commission of India (CCIL) and it will be completed within 15 days from date of the shareholder approval or the date of the CCI approval (whichever is later). The merged listed entity will be named Aster DM Quality Care Limited. Aster DM Quality Care Limited will have a combined portfolio of four leading brands, Aster DM, CARE Hospitals, KIMSHEALTH and Evercare. The combined entity will have a of network of 38 hospitals and more than 10,150 beds spread across 27 cities making it one of the top 3 hospital chains in India. The merger will create a top-3 hospital chain in India, with a strong presence in South and Central India. The combined entity will benefit from a well-diversified network across 9 states, minimal geographic overlap, and a comprehensive healthcare ecosystem encompassing hospitals, labs, clinics, and pharmacies. This strategic combination is expected to unlock significant synergies in revenue, procurement, & supply chain, capex, and integration of corporate functions. Leveraging its strong clinical capabilities, the merged entity is well-positioned for future growth. A robust expansion plan for both brownfield and greenfield is underway, targeting the addition of 3,500 new beds between FY24 and FY27. The transaction is subject to shareholder & regulatory approvals, and other customary conditions to closing. Aster expects the merger transaction to close by Q3 FY26. The ratio for the initial share acquisition is the same as proposed for the merger. Subject to necessary approvals, Aster Promoters and Blackstone will hold equal representation on the board and jointly oversee the merged entity, Dr. Azad Moopen will continue as the executive chairman of the merged entity, Varun Khanna and Sunil Kumar will be promoted to the position of MD & group chief executive officer and group chief financial officer of the merged entity respectively. Aster is valued at a multiple of 36.6x on FY24 adjusted post IND AS EV/ EBITDA. In comparison, QCIL is valued at a multiple of 25.2x based on FY24 adjusted post IND AS EV/ EBITDA. Based on the swap ratio recommended in the valuation report, the resultant shareholding of the Merged Entity will be 24.0% and 30.7% held by Aster Promoters and Blackstone respectively, with the balance 45.3% being held by public and other shareholders. Azad Moopen, founder and chairman of Aster DM Healthcare, said, 'The new combined entity 'Aster DM Quality Care Ltd.' is poised to become one of the largest healthcare players in the industry, setting new benchmarks in patient-centric care, innovation, and accessibility. The Moopen family who has been instrumental in managing Aster's India and GCC businesses will also lead the new merged entity. Thus, by combining the strengths of two pioneers, we are not only expanding our footprint but also creating a transformative force capable of reshaping the healthcare landscape. The integration of Aster and Quality Care's extensive network and deep operational expertise with backing from Blackstone and TPG ' among the most respected private equity firms will enhance our ability to deliver world-class healthcare services, drive innovation, and improve patient outcomes. The merger will also provide our medical professionals with an opportunity to cater to higher and diverse patient inflows.' Varun Khanna, group managing director of Quality Care, said, 'This merger demonstrates our aligned cultures and value systems, and furthers our commitment to address bed shortage in India's underserved regions. The teams at Aster and Quality Care have established a strong legacy of positively impacting patients' lives and meeting the evolving needs of communities. I look forward to leading this platform into a new era focused on healthcare excellence and serving the best interests of the patients.' Aster DM Healthcare is primarily involved in the operations of healthcare facilities, retail pharmacies, and providing consultancy in areas relating to healthcare. The company reported consolidated net profit of Rs 96.84 crore in Q2 FY25 as compared with net loss of Rs 30.80 crore posted in Q2 FY24. Revenue from operations jumped 16.89% year on year (YoY) to Rs 1,086.44 crore during the quarter ended 30 September 2024. The counter added 2.35% to end at Rs 499.95 on Friday, 29 November 2024.Powered by Capital Market - Live